Key messages
In children, allergic bronchopulmonary aspergillosis remains largely
undiagnosed resulting in one of the most common causes of poorly
controlled asthma and significant morbidity in children with cystic
fibrosis.
An early diagnosis allows us to start an earlier treatment of allergic
bronchopulmonary aspergillosis that is crucial for preventing the severe
sequelae such as impairment in lung function, pulmonary fibrosis, and
bronchiectasis.
New, targeted therapies for allergic bronchopulmonary aspergillosis have
emerged as effective options complementing the understanding of
host-Aspergillus interaction.
Firstly described in the United Kingdom in 1952, Allergic
bronchopulmonary aspergillosis (ABPA) is a pulmonary disease caused byAspergillus, principally Aspergillus fumigatus , induced
hypersensitivity that occurs in immunocompetent but susceptible patients
with asthma and/or cystic fibrosis (CF) [1]. The prevalence of ABPA
in the pediatric population is not known. The first pediatric case of
ABPA was reported in 1970, since then only rare case reports and small
case series have been described. ABPA may be found in up to 6% of all
asthmatic patients, and from 2% to 15% in CF patients [1]. Age
more than 12 years, low‑CF index, presence of immunoglobulin (Ig)E and
eosinophilia, bronchial colonization with Stenotrophomonas
maltophilia and Pseudomonas aeruginosa , long‑term azithromycin
therapy, and higher cumulative doses of inhaled corticosteroids (CS)
have been reported as risk factors for ABPA in CF children [2].
At present, the underlying pathophysiology of ABPA is not clearly
understood. Repeated inhalation of Aspergillus spores causes
airway colonization, the release of proteolytic enzymes and
pro-inflammatory cytokines, and, lastly, evokes a T-helper (Th) cell -2
type immune response as well as a polyclonal antibody response leading
to increased serum IgE-, IgG- and IgA antibodies levels [3]. An
impaired balance between human leukocyte antigen (HLA)‑antigen D‑related
molecules associated with susceptibility and resistance to ABPA has been
hypothesized to be also involved in the pathogenesis of ABPA [3].
Clinically, children with ABPA may present both systemic symptoms such
as fever and weight loss, and respiratory symptoms, including poorly
controlled asthma, wheezing, increased productive cough,
tachypnea/dyspnea, chest pain, hemoptysis, and exacerbations responding
poorly to antibiotics. The reported mean age on clinical presentation is
12.9±4 years as a latent period up to 10 years before diagnosis had been
described and male preponderance has been also reported [2]. At
physical examination crackles and rhonchi are usually reported. Patients
with ABPA show a severe progression in all lung function parameters,
and, FEF at 50% VC (FEF50), the volume of trapped gas,
and specific airway resistance as the best predictors have been reported
[1, 2, 4]. Recently, exhaled nitric oxide (FENO) has
been proposed as biomarker for the diagnosis of ABPA in CF [5, 6].
It has been assessed that an early disease recognition may prevent the
progression of ABPA, and, accordingly, clinical and radiographic stages
of ABPA progression have been proposed [7, 8]. The radiographic
findings of ABPA on chest-X-ray are not specific, but pulmonary
infiltrates, consolidation, and macronodular densities are commonly
reported at the early-stage disease, whereas, central bronchiectasis,
ring shadows, and pulmonary fibrosis are reported at the end-stage.
Chest computed tomography (CT) demonstrates high attenuation mucus plugs
and different patterns of central, cylindrical, varicose, and cystic
bronchiectasis, that, involving multiple bronchi, appear described as
“a string of pearls” or “signet ring sign” [7, 8]. Recently,
magnetic resonance imaging (MRI) has also been proposed as a diagnostic
tool in ABPA since it appears highly specific (100%) and sensitive
(94%) for the diagnosis of ABPA in CF, detecting the inverted mucoid
impaction signal, defined by the presence of mucus with both high T1 and
low T2 signal intensities [7, 8]. The diagnostic criteria for ABPA
in children are the same used in the adult population. In addition to
the presence of a predisposing condition such as asthma or CF, patient
must show increased IgE against Aspergillus fumigatus(>0.35 kUA/L), and total serum IgE>1000 IU/ml
(2400 ng/mL), and, at least two out of three secondary criteria must be
satisfied including radiographic transient or fixed findings consistent
with ABPA; serum IgG >27 mg/L against Aspergillus
fumigatus ; and elevated serum eosinophils levels (>500
mmc) [7]. Because of the clinical (pulmonary infiltrate,
bronchiectasis, exacerbations) and radiographic (central bronchiectasis)
findings are similar between ABPA and CF, the diagnosis of ABPA may be
difficult in this cluster of patients. Therefore, the CF Foundation
Consensus has suggested the diagnostic criteria and criteria for
screening for ABPA in CF patients [3]. Detection of acute/subacute
clinical deterioration not related to other etiologies, serum total IgE
concentration major than 1000 IU/mL (or 2400 ng/mL), cutaneous
reactivity to Aspergillus fumigatus, or presence of specific IgE
to Aspergillus fumigatus , precipitating antibodies toAspergillus fumigatus, and new or recent abnormalities on imaging
investigations are defining a patient with CF affected by ABPA [3].
The goals of the treatment of ABPA are to eradicate colonization and/or
proliferation of Aspergillus fumigatus ; suppress inflammatory
response; reduce pulmonary exacerbation and prevent fibrotic end-stage
disease. The most effective treatment for the acute phase of ABPA is
prednisolone at the recommended dosage is 0.5 mg/kg/day for the first 2
weeks, followed by a progressive tapering over the next 12–16 weeks in
patients with asthma [7]; 0.5–2.0 mg/kg/day (maximum 60 mg) for
1–2 weeks, then 0.5–2.0 mg/kg/day every other day for 1–2 weeks, and
then taper in next 2–3 months in patients with CF [3, 7]. There are
several doubts on the efficacy of itraconazole in children with ABPA,
since the available literature data are mainly based on data generated
in adults. Thus, it is not currently recommended as first‑line
treatment. The recommended dose of itraconazole is 5 mg/kg/day, a
maximum 400 mg/day (in two divided doses if the total daily dose exceeds
200 mg) and 3–6 months of a total duration of therapy is suggested
[7]. The evidence of a slow or poor response to CS, relapse of the
disease in CS‑dependent ABPA, and CS‑induced toxicity suggest the use of
itraconazole in treating of ABPA in patients with CF [3, 7]. The
rationale for the use of omalizumab, a humanized monoclonal anti-IgE, in
the ABPA, is due to its ability to prevent allergen-induced
IgE-mediated. This therapy is recommended to be administered as a
subcutaneous injection. The dose and frequency of dosing are guided by a
nomogram derived from total serum IgE level and body weight in
kilograms. Patients with ABPA and treated with omalizumab reported a
significant reduction in exacerbation rates, oral CS exposure, and CS
toxicity [1-3, 9]. Recently, mepolizumab, a monoclonal antibody
against interleukin (IL)-5 has been proposed as an alternative treatment
in ABPA [10]. Other adjuvant therapies such as amphotericin B,
voriconazole, isavuconazole, and vitamin D have been proposed in
treating ABPA, but further studies are required to assess their efficacy
[3]. The monitoring treatment response in ABPA should include the
determination of total serum IgE levels every 3 to 6 months/year since
it has been suggested that a decrease in total IgE levels, at least 25%
from baseline, is associated with a clinical improvement, on the
contrary, an increase by >50% is associated with pulmonary
exacerbations [3]. Spirometry should be performed every 3 to 6
months because of a decline of 15% in functional vital capacity (FVC),
which may be a warning signal of ABPA exacerbation [3]. The
re-evaluation of environmental exposure and chest-X-ray for patients
with IgE level double, even if asymptomatic, should also be performed. A
synacthen test is suggested when adrenal insufficiency is suspected
[3].
In summary, many advances in the understanding of pathophysiology have
been made and several treatment options for ABPA are currently
available. However, whereas in the adult population ABPA is a
well‑recognized entity, in children, it remains mostly undiagnosed,
resulting in one of the most common causes of poorly controlled asthma
and highly significant morbidity in children with CF. An early diagnosis
allows us to start an earlier treatment of ABPA that is crucial for
preventing the severe sequelae such as impairment in lung function,
pulmonary fibrosis, and bronchiectasis.